Viking's Obesity Drug Data Fuels Bets It Can Rival Lilly's Zepbound
Viking Therapeutics reports that patients maintained weight loss on its VK2735 drug, boosting investor confidence in its potential to compete with Eli Lilly.
Markets on this story
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 17% |
| 22 Sept, 19:10 UTC | 17% |
| 22 Sept, 17:54 UTC | 16% |
| 21 Sept, 17:36 UTC | 14% |
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Email me when the odds move
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Viking Therapeutics
- Eli Lilly